San Francisco, 27 March,
Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report
By Route of Administration, By Disease (Diabetes, Lysosomal Disorders), By
Therapy Type, By Region, and Segment Forecasts, 2019 – 2025.
The global metabolic disorder therapeutics market size
is expected to reach USD 88.93 billion by 2025, according to a new report by
Grand View Research, Inc. The market is anticipated to witness a CAGR of 7.56%
during the estimated period. Rising incidences of diabetes, obesity, and
hypercholesterolemia are expected to drive the market growth. It is estimated
that by 2040, about 1 person in 11 people worldwide is likely to suffer from
one of the aforementioned diseases.
Researchers estimate that the prevalence of
metabolic diseases like obesity and diabetes is expected to double in the
coming 2 decades, mainly in U.S. and Asian and Latin American countries. This,
in turn, will help boost the overall market growth in the year to come.
Furthermore, with better economic stability in developing countries, demand for
novel therapeutics for one-time treatment has increased. This has made major
companies in the global market to invest heavily in R&D to develop
innovative therapy options. All these factors will contribute to the
development of the market.
Access Full Research Report On Metabolic Disorder
Therapeutics Analysis:
Further key findings from the study suggest:
·
Diabetes segment led the market in 2017, in
terms of revenue generation,owing to higher prevalence and drug usage
·
Obesity segment is expected to register a
CAGR of 9.27% over the forecast period owing to increasing prevalence as a
result of sedentary lifestyle changes
·
Drug therapy was the most-preferred therapy
due to its high reliability proven success and availability of various types of
drugs to treat metabolic diseases
·
The segment is expected to maintain its
dominance even during the forecast years due to the introduction of smart
technology to deliver antidiabetic drug on a regulated basis
·
Key companies in this market are Novo
Nordisk A/S;Sanofi S.A.; BoehringerIngelheim GmbH; Eli Lilly and Company; Merck
KgaA; Amgen, Inc.; AstraZeneca PLC; Actelion Pharmaceuticals Ltd.; Shire PLC;
AbbVie, Inc.;Biocon Ltd.;BioMarinPharmaceutical, Inc.; Bristol-Myers Squibb
Company; Cipla, Inc.; and CymaBay Therapeutics, Inc.
·
Most of these companies are focusing on
strategies, such as collaborations, expansion of product portfolios, and
M&A to maintain their industry position
·
Oral route of administration was the key
revenue-generating segment in 2017owing to its benefits, such as high
reliability and ease of administration
·
North America was the largest regional
market in 2017 and will maintain the trend in future due to the presence of key
companies and rising cases of diabetes and obesity
Browse
More Reports Of This Category By Grand View Research At: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global metabolic disorder
therapeutics market on the basis of disease, therapy type, route of
administration, and region:
Metabolic Disorder Therapeutics Disease
Outlook (Revenue, USD Billion, 2014 - 2025)
·
Lysosomal Storage Diseases
o
Gaucher’s Disease
o
Metachromatic Leukodystrophy
o
Hurler - Scheie
o
Sanfilipo A
o
Others
·
Diabetes
·
Obesity
·
Inherited Metabolic Disorders
·
Hypercholesterolemia
Metabolic Disorder Therapy Type
Outlook (Revenue, USD Billion, 2014 - 2025)
·
Enzyme Replacement Therapy
·
Cellular Transplantation
·
Small Molecule Based Therapy
·
Substrate Reduction Therapy
·
Gene Therapy
·
Drug Therapy
Metabolic Disorder Therapeutics Route
of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
·
Oral
·
Parenteral
·
Others
Metabolic Disorder Therapeutics Regional
Outlook (Revenue, USD Billion, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
U.K.
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
·
Middle East & Africa
o
South Africa
Access Full Press Release of this Report: https://www.grandviewresearch.com/press-release/global-metabolic-disorder-therapeutics-market
About Grand View Research
Grand View Research, Inc. is a U.S. based
market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment